Jazz Pharmaceuticals (JAZZ) Receives a Buy from Piper Sandler
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Jazz Pharmaceuticals, with a price target of $219.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Amsellem is a 4-star analyst with an average return of 6.6% and a 51.30% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, AbbVie, and Biogen.
In a report released on January 16, Wells Fargo also maintained a Buy rating on the stock with a $235.00 price target.
Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.13 billion and a net profit of $251.41 million. In comparison, last year the company earned a revenue of $1.05 billion and had a net profit of $215.06 million
Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Last month, Mary Elizabeth Henderson, the SVP Tech. Op of JAZZ sold 2,238.00 shares for a total of $379,363.38.
Read More on JAZZ:
Disclaimer & DisclosureReport an Issue
- Jazz Pharmaceuticals price target raised to $230 from $220 at Truist
- Jazz Pharmaceuticals price target raised to $235 from $210 at Needham
- BofA ups Jazz Pharmaceuticals price target, says selloff ‘unwarranted’
- Closing Bell Movers: AXT Inc. slips after cutting Q4 revenue guidance
- Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer
